| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Testosterone | 83 | 2025 | 611 | 16.930 |
Why?
|
| Hypogonadism | 55 | 2025 | 320 | 14.490 |
Why?
|
| Erectile Dysfunction | 40 | 2025 | 211 | 12.860 |
Why?
|
| Hormone Replacement Therapy | 40 | 2025 | 211 | 10.220 |
Why?
|
| Prostatic Neoplasms | 34 | 2025 | 1577 | 5.760 |
Why?
|
| Androgens | 18 | 2025 | 277 | 4.810 |
Why?
|
| Penile Prosthesis | 11 | 2024 | 41 | 4.060 |
Why?
|
| Penile Implantation | 8 | 2024 | 25 | 3.650 |
Why?
|
| Prostatectomy | 20 | 2022 | 359 | 2.660 |
Why?
|
| Cardiovascular Diseases | 22 | 2025 | 2092 | 2.620 |
Why?
|
| Prostate-Specific Antigen | 13 | 2025 | 271 | 2.290 |
Why?
|
| Penile Induration | 5 | 2024 | 38 | 2.270 |
Why?
|
| Penile Erection | 16 | 2023 | 86 | 2.260 |
Why?
|
| Male | 139 | 2025 | 64985 | 2.200 |
Why?
|
| Urology | 5 | 2025 | 87 | 2.130 |
Why?
|
| Sexual Dysfunction, Physiological | 8 | 2025 | 92 | 1.800 |
Why?
|
| Libido | 5 | 2022 | 37 | 1.590 |
Why?
|
| Patient Satisfaction | 9 | 2025 | 486 | 1.520 |
Why?
|
| Humans | 143 | 2025 | 132132 | 1.500 |
Why?
|
| Stem Cell Transplantation | 3 | 2024 | 249 | 1.500 |
Why?
|
| Penis | 10 | 2025 | 101 | 1.410 |
Why?
|
| Sexual Behavior | 9 | 2024 | 250 | 1.200 |
Why?
|
| Sexual Health | 2 | 2025 | 14 | 1.080 |
Why?
|
| Middle Aged | 51 | 2025 | 29003 | 1.000 |
Why?
|
| Depression | 5 | 2018 | 1342 | 0.990 |
Why?
|
| Urologists | 1 | 2025 | 12 | 0.920 |
Why?
|
| Aged | 43 | 2025 | 21442 | 0.920 |
Why?
|
| Holistic Health | 1 | 2025 | 12 | 0.910 |
Why?
|
| Finasteride | 2 | 2022 | 18 | 0.890 |
Why?
|
| Microbial Collagenase | 1 | 2024 | 10 | 0.880 |
Why?
|
| Platelet-Rich Plasma | 1 | 2024 | 19 | 0.880 |
Why?
|
| Commerce | 1 | 2025 | 58 | 0.880 |
Why?
|
| Watchful Waiting | 1 | 2025 | 77 | 0.870 |
Why?
|
| Reproductive Health | 2 | 2024 | 49 | 0.860 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2023 | 21 | 0.830 |
Why?
|
| Androgen Antagonists | 2 | 2024 | 133 | 0.830 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2025 | 123 | 0.820 |
Why?
|
| Career Choice | 1 | 2025 | 160 | 0.820 |
Why?
|
| Health Care Costs | 3 | 2018 | 414 | 0.810 |
Why?
|
| Surveys and Questionnaires | 13 | 2025 | 4003 | 0.810 |
Why?
|
| Prosthesis Design | 4 | 2024 | 670 | 0.760 |
Why?
|
| Urinary Sphincter, Artificial | 1 | 2021 | 6 | 0.730 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2021 | 34 | 0.720 |
Why?
|
| Adult | 37 | 2025 | 31585 | 0.720 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2021 | 14 | 0.710 |
Why?
|
| Retrospective Studies | 25 | 2025 | 17424 | 0.700 |
Why?
|
| Cystic Fibrosis | 1 | 2024 | 264 | 0.690 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 324 | 0.690 |
Why?
|
| Polycythemia | 1 | 2020 | 45 | 0.660 |
Why?
|
| Telemedicine | 2 | 2024 | 495 | 0.650 |
Why?
|
| Eunuchism | 2 | 2022 | 7 | 0.640 |
Why?
|
| Treatment Outcome | 23 | 2024 | 13034 | 0.640 |
Why?
|
| Curriculum | 1 | 2024 | 772 | 0.600 |
Why?
|
| Fertility | 2 | 2018 | 258 | 0.600 |
Why?
|
| Prostate | 4 | 2023 | 437 | 0.600 |
Why?
|
| Clomiphene | 1 | 2018 | 16 | 0.580 |
Why?
|
| North America | 7 | 2024 | 265 | 0.580 |
Why?
|
| Botulinum Toxins, Type A | 3 | 2005 | 164 | 0.570 |
Why?
|
| Spinal Cord Injuries | 3 | 2007 | 287 | 0.560 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2017 | 53 | 0.540 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 78 | 0.530 |
Why?
|
| Societies, Medical | 5 | 2024 | 779 | 0.520 |
Why?
|
| Quality of Life | 8 | 2025 | 2161 | 0.510 |
Why?
|
| Varicocele | 4 | 2010 | 61 | 0.500 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2017 | 258 | 0.480 |
Why?
|
| Prospective Studies | 12 | 2025 | 6571 | 0.480 |
Why?
|
| Abdominal Wall | 1 | 2015 | 26 | 0.470 |
Why?
|
| Postoperative Complications | 7 | 2024 | 3143 | 0.450 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2024 | 1248 | 0.450 |
Why?
|
| Impotence, Vasculogenic | 2 | 2014 | 9 | 0.450 |
Why?
|
| Mass Screening | 2 | 2024 | 830 | 0.440 |
Why?
|
| Comorbidity | 7 | 2018 | 1611 | 0.440 |
Why?
|
| Medication Adherence | 1 | 2018 | 329 | 0.440 |
Why?
|
| Men's Health | 3 | 2024 | 21 | 0.430 |
Why?
|
| Drug Implants | 5 | 2015 | 45 | 0.430 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2015 | 87 | 0.430 |
Why?
|
| Prostatic Hyperplasia | 3 | 2023 | 122 | 0.410 |
Why?
|
| Urinary Bladder | 2 | 2005 | 254 | 0.410 |
Why?
|
| United States | 18 | 2023 | 11668 | 0.410 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2013 | 45 | 0.410 |
Why?
|
| Pandemics | 1 | 2021 | 1183 | 0.400 |
Why?
|
| Extracorporeal Shockwave Therapy | 2 | 2024 | 9 | 0.390 |
Why?
|
| Osteoporotic Fractures | 1 | 2012 | 30 | 0.380 |
Why?
|
| Carcinoma | 1 | 2015 | 299 | 0.370 |
Why?
|
| Registries | 9 | 2018 | 1581 | 0.370 |
Why?
|
| Urologic Diseases | 2 | 2023 | 45 | 0.370 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 482 | 0.360 |
Why?
|
| Klinefelter Syndrome | 1 | 2011 | 21 | 0.360 |
Why?
|
| Brachytherapy | 1 | 2012 | 95 | 0.360 |
Why?
|
| Deficiency Diseases | 1 | 2011 | 9 | 0.350 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2011 | 53 | 0.350 |
Why?
|
| Aging | 2 | 2016 | 1250 | 0.350 |
Why?
|
| Heart Diseases | 1 | 2016 | 513 | 0.350 |
Why?
|
| Coitus | 2 | 2025 | 21 | 0.340 |
Why?
|
| Patient Compliance | 2 | 2011 | 473 | 0.340 |
Why?
|
| Public Health | 1 | 2012 | 281 | 0.330 |
Why?
|
| Nitric Oxide | 1 | 2013 | 471 | 0.320 |
Why?
|
| Risk Factors | 12 | 2021 | 10949 | 0.320 |
Why?
|
| Aged, 80 and over | 12 | 2023 | 7108 | 0.310 |
Why?
|
| Prevalence | 4 | 2018 | 2658 | 0.310 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 323 | 0.310 |
Why?
|
| Estradiol | 4 | 2021 | 487 | 0.300 |
Why?
|
| Urologic Surgical Procedures, Male | 3 | 2019 | 36 | 0.300 |
Why?
|
| Cardiovascular System | 3 | 2021 | 107 | 0.300 |
Why?
|
| Medicare | 5 | 2023 | 448 | 0.300 |
Why?
|
| Administration, Oral | 3 | 2025 | 698 | 0.280 |
Why?
|
| Disease Progression | 3 | 2025 | 2226 | 0.270 |
Why?
|
| Operative Time | 3 | 2018 | 195 | 0.270 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2015 | 1222 | 0.270 |
Why?
|
| Gels | 4 | 2023 | 72 | 0.270 |
Why?
|
| Animals | 12 | 2025 | 34882 | 0.270 |
Why?
|
| Receptors, Epoprostenol | 1 | 2007 | 7 | 0.260 |
Why?
|
| Cell Proliferation | 1 | 2014 | 2508 | 0.260 |
Why?
|
| Databases, Factual | 3 | 2023 | 1230 | 0.260 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2007 | 30 | 0.250 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2007 | 46 | 0.250 |
Why?
|
| Linear Models | 3 | 2013 | 713 | 0.250 |
Why?
|
| Behavior Therapy | 2 | 2023 | 269 | 0.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 743 | 0.250 |
Why?
|
| Female | 13 | 2025 | 70725 | 0.240 |
Why?
|
| Incidence | 5 | 2021 | 3381 | 0.240 |
Why?
|
| Neoplasm Grading | 3 | 2021 | 300 | 0.240 |
Why?
|
| Urinary Incontinence | 1 | 2006 | 78 | 0.240 |
Why?
|
| Sensation | 1 | 2005 | 51 | 0.230 |
Why?
|
| Muscle Strength | 1 | 2025 | 87 | 0.230 |
Why?
|
| Neurotoxins | 1 | 2005 | 58 | 0.230 |
Why?
|
| Biomarkers | 3 | 2025 | 3405 | 0.230 |
Why?
|
| Liver Function Tests | 1 | 2025 | 102 | 0.220 |
Why?
|
| Mice, Nude | 2 | 2017 | 752 | 0.220 |
Why?
|
| Sexology | 1 | 2024 | 5 | 0.220 |
Why?
|
| Rats | 6 | 2020 | 3611 | 0.220 |
Why?
|
| Spermatogenesis | 2 | 2018 | 176 | 0.220 |
Why?
|
| Injections, Intralesional | 1 | 2024 | 47 | 0.220 |
Why?
|
| Urethral Stricture | 1 | 2004 | 15 | 0.220 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2025 | 152 | 0.220 |
Why?
|
| Semen Analysis | 1 | 2024 | 34 | 0.220 |
Why?
|
| Cosmetic Techniques | 1 | 2024 | 11 | 0.220 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 3681 | 0.210 |
Why?
|
| Blood Pressure | 3 | 2021 | 1400 | 0.210 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2024 | 47 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 1408 | 0.210 |
Why?
|
| Urinary Retention | 1 | 2023 | 19 | 0.210 |
Why?
|
| Adenosine Triphosphate | 1 | 2004 | 275 | 0.210 |
Why?
|
| Cholesterol, HDL | 1 | 2025 | 398 | 0.210 |
Why?
|
| Alprostadil | 2 | 2016 | 22 | 0.210 |
Why?
|
| Neuromuscular Agents | 1 | 2004 | 66 | 0.210 |
Why?
|
| Neurocognitive Disorders | 1 | 2024 | 78 | 0.200 |
Why?
|
| Bayes Theorem | 1 | 2024 | 311 | 0.200 |
Why?
|
| Health Expenditures | 2 | 2016 | 133 | 0.200 |
Why?
|
| Time Factors | 4 | 2024 | 6454 | 0.200 |
Why?
|
| Patient Preference | 1 | 2025 | 141 | 0.200 |
Why?
|
| Receptors, Androgen | 3 | 2014 | 409 | 0.190 |
Why?
|
| Triglycerides | 1 | 2025 | 617 | 0.190 |
Why?
|
| Drug Administration Schedule | 3 | 2013 | 749 | 0.190 |
Why?
|
| Cholesterol | 1 | 2025 | 558 | 0.190 |
Why?
|
| Priapism | 1 | 2022 | 12 | 0.190 |
Why?
|
| Insurance Coverage | 1 | 2023 | 127 | 0.190 |
Why?
|
| Sildenafil Citrate | 2 | 2013 | 57 | 0.190 |
Why?
|
| Young Adult | 9 | 2024 | 9961 | 0.190 |
Why?
|
| Clinical Trials as Topic | 2 | 2025 | 1163 | 0.180 |
Why?
|
| Life Style | 1 | 2025 | 453 | 0.180 |
Why?
|
| Patient Education as Topic | 1 | 2025 | 465 | 0.180 |
Why?
|
| Biopsy | 1 | 2025 | 1284 | 0.170 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1500 | 0.170 |
Why?
|
| Orchiectomy | 2 | 2017 | 54 | 0.160 |
Why?
|
| Lung Transplantation | 1 | 2024 | 335 | 0.160 |
Why?
|
| Traction | 1 | 2019 | 9 | 0.160 |
Why?
|
| Azoospermia | 2 | 2010 | 48 | 0.160 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 2 | 2016 | 36 | 0.150 |
Why?
|
| Placenta | 1 | 2023 | 540 | 0.150 |
Why?
|
| Regenerative Medicine | 1 | 2019 | 35 | 0.150 |
Why?
|
| Muscle, Skeletal | 1 | 2025 | 1036 | 0.150 |
Why?
|
| Single-Blind Method | 1 | 2019 | 243 | 0.150 |
Why?
|
| Dementia | 1 | 2024 | 459 | 0.150 |
Why?
|
| Insurance, Health | 1 | 2019 | 144 | 0.150 |
Why?
|
| Lipids | 3 | 2023 | 561 | 0.140 |
Why?
|
| Infertility, Male | 3 | 2024 | 296 | 0.140 |
Why?
|
| Anemia, Sickle Cell | 1 | 2022 | 329 | 0.140 |
Why?
|
| Reoperation | 1 | 2021 | 853 | 0.140 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2018 | 68 | 0.140 |
Why?
|
| Hematocrit | 2 | 2021 | 112 | 0.140 |
Why?
|
| Chorionic Gonadotropin | 1 | 2018 | 81 | 0.140 |
Why?
|
| Estrogen Antagonists | 1 | 2018 | 97 | 0.140 |
Why?
|
| Organ Transplantation | 1 | 2020 | 180 | 0.140 |
Why?
|
| Sex Hormone-Binding Globulin | 3 | 2014 | 50 | 0.140 |
Why?
|
| Double-Blind Method | 3 | 2023 | 1658 | 0.140 |
Why?
|
| Caffeine | 1 | 2018 | 65 | 0.140 |
Why?
|
| Health Status | 2 | 2010 | 408 | 0.140 |
Why?
|
| Exercise | 1 | 2023 | 858 | 0.140 |
Why?
|
| Liver | 1 | 2025 | 1797 | 0.130 |
Why?
|
| Recovery of Function | 4 | 2022 | 462 | 0.130 |
Why?
|
| Pilot Projects | 2 | 2024 | 1452 | 0.130 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 1659 | 0.130 |
Why?
|
| Tumor Burden | 1 | 2017 | 246 | 0.130 |
Why?
|
| Gene Expression | 1 | 2021 | 1558 | 0.130 |
Why?
|
| Diabetes Complications | 2 | 2015 | 207 | 0.130 |
Why?
|
| Dosage Forms | 1 | 2016 | 9 | 0.120 |
Why?
|
| Administration, Cutaneous | 2 | 2013 | 67 | 0.120 |
Why?
|
| Thrombosis | 1 | 2021 | 524 | 0.120 |
Why?
|
| Fasciotomy | 1 | 2015 | 26 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2020 | 5169 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 307 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 5419 | 0.120 |
Why?
|
| Personal Satisfaction | 2 | 2013 | 106 | 0.110 |
Why?
|
| Age Distribution | 1 | 2016 | 438 | 0.110 |
Why?
|
| Endothelium, Vascular | 2 | 2017 | 487 | 0.110 |
Why?
|
| Heterografts | 1 | 2015 | 197 | 0.110 |
Why?
|
| Vulvodynia | 1 | 2014 | 3 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 167 | 0.110 |
Why?
|
| Endocrinology | 1 | 2017 | 128 | 0.110 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2015 | 40 | 0.110 |
Why?
|
| Luteinizing Hormone | 4 | 2015 | 136 | 0.110 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2014 | 20 | 0.110 |
Why?
|
| Heart Rate | 1 | 2017 | 591 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2015 | 272 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 2 | 2015 | 576 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 990 | 0.110 |
Why?
|
| Nanostructures | 1 | 2014 | 64 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3418 | 0.110 |
Why?
|
| Reproduction | 1 | 2016 | 226 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2015 | 386 | 0.110 |
Why?
|
| Androgen-Insensitivity Syndrome | 1 | 2013 | 26 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2015 | 136 | 0.100 |
Why?
|
| Postoperative Period | 3 | 2022 | 335 | 0.100 |
Why?
|
| Nitric Oxide Synthase | 2 | 2016 | 175 | 0.100 |
Why?
|
| Streptozocin | 1 | 2013 | 26 | 0.100 |
Why?
|
| Microspheres | 1 | 2013 | 73 | 0.100 |
Why?
|
| Bone Density | 1 | 2016 | 367 | 0.100 |
Why?
|
| Disease Management | 1 | 2017 | 563 | 0.100 |
Why?
|
| Sulfones | 1 | 2013 | 73 | 0.100 |
Why?
|
| Body Composition | 1 | 2016 | 550 | 0.100 |
Why?
|
| Purines | 1 | 2013 | 113 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 143 | 0.100 |
Why?
|
| Adolescent | 5 | 2022 | 20564 | 0.100 |
Why?
|
| Decision Making | 1 | 2018 | 703 | 0.100 |
Why?
|
| Health Surveys | 2 | 2011 | 259 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 2014 | 151 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2013 | 192 | 0.100 |
Why?
|
| Pregnancy | 2 | 2023 | 7566 | 0.090 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2013 | 145 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2021 | 3739 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 435 | 0.090 |
Why?
|
| Tadalafil | 1 | 2011 | 4 | 0.090 |
Why?
|
| Hemoglobins | 1 | 2013 | 322 | 0.090 |
Why?
|
| Piperazines | 1 | 2013 | 257 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 803 | 0.090 |
Why?
|
| Prosthesis-Related Infections | 1 | 2013 | 188 | 0.090 |
Why?
|
| Muscle Contraction | 2 | 2016 | 155 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1011 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 768 | 0.090 |
Why?
|
| Sexual Partners | 1 | 2011 | 85 | 0.080 |
Why?
|
| Drug Monitoring | 1 | 2012 | 174 | 0.080 |
Why?
|
| Logistic Models | 2 | 2018 | 1839 | 0.080 |
Why?
|
| Insulin Resistance | 1 | 2016 | 697 | 0.080 |
Why?
|
| Risk | 1 | 2012 | 761 | 0.080 |
Why?
|
| Chronic Disease | 2 | 2005 | 1234 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2018 | 1697 | 0.080 |
Why?
|
| Cause of Death | 1 | 2012 | 510 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2011 | 239 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2010 | 128 | 0.080 |
Why?
|
| Sexuality | 1 | 2009 | 13 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 1180 | 0.080 |
Why?
|
| Organ Size | 1 | 2010 | 449 | 0.080 |
Why?
|
| Program Development | 1 | 2010 | 192 | 0.080 |
Why?
|
| Pregnancy Outcome | 1 | 2012 | 637 | 0.080 |
Why?
|
| Mice | 2 | 2017 | 18507 | 0.080 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2009 | 6 | 0.080 |
Why?
|
| Patient Safety | 1 | 2014 | 440 | 0.080 |
Why?
|
| Vasodilator Agents | 1 | 2010 | 207 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2012 | 1573 | 0.070 |
Why?
|
| Age Factors | 4 | 2019 | 2917 | 0.070 |
Why?
|
| Evidence-Based Medicine | 3 | 2017 | 663 | 0.070 |
Why?
|
| Veins | 1 | 2009 | 104 | 0.070 |
Why?
|
| Laparoscopy | 2 | 2013 | 523 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 3766 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2010 | 368 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2012 | 471 | 0.070 |
Why?
|
| Embolization, Therapeutic | 1 | 2009 | 223 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2010 | 1254 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 4688 | 0.060 |
Why?
|
| Sex Factors | 1 | 2010 | 1356 | 0.060 |
Why?
|
| International Cooperation | 2 | 2017 | 164 | 0.060 |
Why?
|
| Hand Strength | 1 | 2025 | 61 | 0.060 |
Why?
|
| Masturbation | 1 | 2025 | 2 | 0.060 |
Why?
|
| Constriction | 1 | 2025 | 47 | 0.060 |
Why?
|
| Recurrence | 2 | 2009 | 1471 | 0.060 |
Why?
|
| Sarcopenia | 1 | 2025 | 57 | 0.060 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 553 | 0.050 |
Why?
|
| Urothelium | 1 | 2004 | 59 | 0.050 |
Why?
|
| Retreatment | 1 | 2004 | 93 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2015 | 193 | 0.050 |
Why?
|
| Random Allocation | 1 | 2025 | 430 | 0.050 |
Why?
|
| Transdermal Patch | 1 | 2023 | 8 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 3093 | 0.050 |
Why?
|
| Phenylephrine | 1 | 2022 | 40 | 0.050 |
Why?
|
| Testosterone Congeners | 1 | 2022 | 17 | 0.050 |
Why?
|
| Equivalence Trials as Topic | 1 | 2021 | 24 | 0.050 |
Why?
|
| Isotretinoin | 1 | 2022 | 19 | 0.050 |
Why?
|
| Prosthesis Failure | 1 | 2022 | 164 | 0.040 |
Why?
|
| Monitoring, Ambulatory | 1 | 2021 | 58 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 309 | 0.040 |
Why?
|
| HIV Infections | 1 | 2013 | 2038 | 0.040 |
Why?
|
| SEER Program | 1 | 2021 | 220 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2022 | 327 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 1302 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2018 | 95 | 0.030 |
Why?
|
| Critical Pathways | 1 | 2018 | 75 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 160 | 0.030 |
Why?
|
| Polypharmacy | 1 | 2017 | 36 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 1362 | 0.030 |
Why?
|
| Survival Rate | 1 | 2022 | 2194 | 0.030 |
Why?
|
| Premature Ejaculation | 1 | 2016 | 4 | 0.030 |
Why?
|
| Child | 3 | 2022 | 25791 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2018 | 314 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 2016 | 131 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1460 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 1047 | 0.030 |
Why?
|
| Patient Participation | 1 | 2018 | 240 | 0.030 |
Why?
|
| 2-Hydroxypropyl-beta-cyclodextrin | 1 | 2014 | 4 | 0.030 |
Why?
|
| beta-Cyclodextrins | 1 | 2014 | 12 | 0.030 |
Why?
|
| Stroke | 1 | 2023 | 1085 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2014 | 60 | 0.030 |
Why?
|
| Trinucleotide Repeats | 1 | 2014 | 108 | 0.030 |
Why?
|
| Patient Admission | 1 | 2015 | 185 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2014 | 41 | 0.030 |
Why?
|
| Manometry | 1 | 2014 | 72 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 225 | 0.020 |
Why?
|
| Arteries | 1 | 2014 | 222 | 0.020 |
Why?
|
| Kinetics | 1 | 2014 | 1130 | 0.020 |
Why?
|
| Canada | 1 | 2013 | 338 | 0.020 |
Why?
|
| Robotics | 1 | 2013 | 108 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2011 | 39 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 708 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 737 | 0.020 |
Why?
|
| Affect | 1 | 2011 | 173 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 1686 | 0.020 |
Why?
|
| Ligation | 1 | 2009 | 140 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 2697 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2009 | 187 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1728 | 0.020 |
Why?
|
| Equipment Design | 1 | 2009 | 614 | 0.020 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 364 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 819 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2011 | 1123 | 0.020 |
Why?
|
| Obesity | 1 | 2011 | 2393 | 0.010 |
Why?
|